06.03.2019
Filing of new US provisional patent application
Filing of new US provisional patent application
28.02.2019
Board Meeting No 2 2019
March 5th 2019. 
23.01.2019
Regenics Board Meeting No 1 2019
January 23rd 2019.  
23.01.2019
Protocol Extraordinary Annual Meeting January 23rd 2019
January 23rd 2019 Protocoll of Extraordinary Annual Meeting January 23rd 2019. The Extraordinary Annual Meeting 2019 took place in the Companys office, Karvesvingen. 2, Oslo
18.12.2018
New EPO Patent granted 2018
New EPO patent
10.12.2018
Eqology AS launch Collagen Booster Serum
 An important commercial milestone has been reached for Regenics December 10th with the launch of the ground breaking EQ Collagen Boosting Serum from the Norwegian Direct Selling Company Eqology AS.  
30.11.2018
Protocol from Extraordinary Annual Meeting September 26th 2018
September 26th 2018 Protocol of Extraordinary Annual Meeting September 26th 2018. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
29.11.2018
Notification of grant:Divisional EPO patent
Notification of grant: Divisional EPO patent
07.11.2018
Regenics Board Meeting No 4 2018
November 7th 2018
17.09.2018
Bernat Rocarols - R&D Engineer Regenics
   
09.09.2018
Regenics Board Meeting No 3 2018
September 9th 2018
19.08.2018
EPO National validation 2018
EPO Patent validation 
30.06.2018
Regenics Board Meeting No 2 2018
June 13th 2018
28.06.2018
Protocol Annual Meeting 2018
June 28th 2018 Protocoll of Regenics Annual Meeting on June 28th 2018. The Annual Meeting 2018 took place in the Companys office, Karvesvingen. 2, Oslo
19.06.2018
US patent granted June 2018
 
15.06.2018
Upcoming event: 37C Health Meeting Stavanger
Regenics AS attends the 37C "Digitalization in Health" meeting on June 19-20 of June 2018 at Forus Stavanger. CEO Henrik Lund, co-chairs the meeting    
13.06.2018
Regenics AS Annual Report 2017
Regenics post a small positive 2017 result with topline in excess of 0.047 mill NOK. 
13.06.2018
Notice and Protocol of Annual Meeting 2018
June 13th 2018 Notice of Annual Meeting June 28th 2018. The Annual Meeting 2018 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
23.05.2018
Innovation Norway grants Innovation Contract to Regenics AS
Regenics AS was May 18th 2018 awarded an Innovation Contract from Innovation Norway. The Innovation Contract has a total budget of 14.3 million NOK to support the development of Vernex®...
07.05.2018
Updated share info May 7th 2018
Regenics AS provides updated share info and shareowner distribution as per May 7th 2018
02.03.2018
Regenics Board Meeting No 1 2018
March 2nd 2018
03.01.2018
Protocol from Extraordinary Annual Meeting December 15th 2017
December 15th 2017 Protocoll of Extraordinary Annual Meeting December 15th 2017. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
03.01.2018
Succesfull placement of share issue December 2017
According to resolutions by the Board of Directors on December 15th 2017 a limited private placement of a total of 129.729 shares at a price of 17.15 NOK per share...
27.11.2017
Publication: Japan-US researchers shows pacific roe boosting collagen mRNA production in skin cells
Pacific chum salmon roe extracts show boosting of collagen I mRNA production in skin cells and induction of anti-oxidative genes.

<<  <   Page 2 of 5   >  >>

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.